Promising Phase 1 Results and Strong Efficacy Signals Drive Buy Rating for Zentalis Pharmaceuticals’ Azenosertib

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report). The associated price target remains the same with $10.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the potential of Zentalis Pharmaceuticals’ azenosertib in treating specific cancer types. The recent Phase 1 study results presented at the ASCO Annual Meeting demonstrated the safety and preliminary efficacy of azenosertib, particularly in combination with other agents for treating BRAF V600E-mutant metastatic colorectal cancer (mCRC). This study showed that azenosertib, when used in a triplet regimen, was generally well tolerated and did not present dose-limiting toxicities at the recommended Phase 2 dose.
Additionally, the clinical data indicated strong efficacy signals in patients who had not previously received BRAF inhibitors, with a high overall response rate and disease control rate. The favorable safety profile of azenosertib’s triplet combination, compared to other regimens, further supports its potential as a more tolerable treatment option. These findings collectively suggest that azenosertib could improve outcomes for patients with BRAF V600E-mutant mCRC, making it a promising candidate for further development and a key factor in the Buy rating for Zentalis Pharmaceuticals’ stock.

In another report released on May 15, Oppenheimer also reiterated a Buy rating on the stock with a $9.00 price target.